# Mamotest

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mamotest

- Industry: Healthcare
- Headquarters: Buenos Aires, Argentina
- Website: www.mamotest.com
- Total disclosed funding: $3.3M
- Latest round: Series A (Mar 27, 2023)
- Investors on record: 5

## About

Based in Argentina, and founded in 2013, Mamotest provides an AI platform for the diagnosis of breast cancer in patients. As of 2023, the company is headed by its CEO Guillermo Pepe. In March 2023, the firm raised USD 3.3 million in Series A funding led by investor Johnson & Johnson Impact Ventures, with participation from other investors Sky High and Sonen Capital. Returning investors Merck & Co., Inc., Banco Comafi, and other investors also participated in the round.

The company offers an artificial intelligence-based platform for early screening and diagnosis of breast cancer. The firm provides a wide range of services such as 3D mammography, breast ultrasound, stereotactic biopsy, and many others services.

The company plans to use the March 2023 funding to grow and expand its business.

## Funding rounds

- Series A, Mar 27, 2023, $3.3M — Merck & Co., Inc., Sonen Capital, Banco Comafi, Johnson & Johnson Impact Ventures, Sky High

## Investors

- Merck & Co., Inc. — Series A
- Sonen Capital (https://capitalatlas.ai/funds/sonen-capital) — Series A
- Banco Comafi — Series A
- Johnson & Johnson Impact Ventures (https://capitalatlas.ai/funds/johnson-johnson-impact-ventures) — Series A
- Sky High — Series A